ArticleGM crops & food2022
Strategic science translation in emerging science: genetically modified crops and Bisphenol A in two cases of contested animal toxicity studies.
Article in GM crops & food, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When controversies develop around scientific facts or technologies, the potential of science to become a tool in plays of interests and power between different actors is not well recognized. Cordner's concept of Strategic Science Translation (SST) shows that such actions are enabled by the uncertainty and the complexity of the scientific processes that allow the use of science in support of various, often contradictory interests and goals. Two high-profile controversies around animal toxicity studies in two different fields of European regulatory science (genetically modified food and food contact materials) were chosen as case studies to explore and expand the SST concept. Both studies involve emerging science issues, emphasizing tensions between regulatory and academic science. Communications from key Civil Society Organizations (CSOs) and industry groups were used for analysis of each controversy. We found that both groups of actors try to present their own interpretation of scientific results, taking advantage of the lack of scientific consensus, of the uncertainties associated with the negotiation in the interpretation of results, and of the wider scientific and political context. In the same time, each actor attempts to challenge the credibility of the other. The lack of formal acknowledgment of the limitations of the emerging scientific fields, as well as of different research approaches between regulatory and academic research contribute to the continuation of controversies in the public domain, as the public cannot easily assess the information presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.